Patents Examined by Jon M. Lockard
  • Patent number: 10815306
    Abstract: Humanized or chimeric anti-CD81 (cluster of differentiation 81) monoclonal antibodies are provided. The antibodies bind to human CD81, and find use in various therapeutic methods, including without limitation the reduction or prevention of tumor metastasis. Further provided are heavy chain and light chain variable region sequences as well as associated complementarity-determining region (CDR) sequences.
    Type: Grant
    Filed: June 14, 2017
    Date of Patent: October 27, 2020
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Shoshana Levy, Aurelien Marabelle, Ranjani Rajapaksa, Felipe Vences-Catalan, Chiung-Chi Kuo, Jie Liu, Ronald Levy
  • Patent number: 10793637
    Abstract: The present disclosure relates to anti-CD39 antibodies, and antigen binding portions thereof and their use in treating cancer.
    Type: Grant
    Filed: May 13, 2020
    Date of Patent: October 6, 2020
    Assignee: Surface Oncology, Inc.
    Inventors: Scott Chappel, Andrew Lake, Michael Warren, Austin Dulak, Erik Devereaux, Pamela M. Holland, Tauqeer Zaidi, Matthew Rausch, Bianka Prinz, Nels P. Nielson, Sonia Das
  • Patent number: 10787497
    Abstract: The present invention relates to a cancer treatment composition for inhibiting angiogenesis, and a preparation method therefor. An angiogenesis inhibitor according to the present invention is a cancer treatment composition comprising a fusion protein comprising a vascular endothelial growth factor-binding domain of vascular endothelial growth factor receptor 1 (VEGFR1) and a b1 domain of neuropilin-1 (NRP1). The novel fusion protein is an angiogenesis inhibitor for blocking the binding of VEGF to a receptor in the cell membrane, and has an effect of inhibiting the proliferation of cancer cells and the growth and metastasis of cancer. In addition, the fusion protein can be used as an anti-cancer agent and exhibits an effective anti-cancer effect at a lower dose than that of a conventional angiogenesis inhibitor.
    Type: Grant
    Filed: July 5, 2016
    Date of Patent: September 29, 2020
    Assignee: IBENTRUS, INC.
    Inventors: Hoeon Kim, Hyun-ju Lee
  • Patent number: 10780121
    Abstract: The present invention relates, inter alia, to compositions and methods, including chimeric proteins comprising an extracellular domain of FMS like tyrosine kinase 3 ligand (FLT3L) and an extracellular domain of a Type II transmembrane protein that find use in the treatment of disease, such as cancer.
    Type: Grant
    Filed: September 13, 2019
    Date of Patent: September 22, 2020
    Assignee: Shattuck Labs, Inc.
    Inventors: Taylor Schreiber, George Fromm, Suresh De Silva
  • Patent number: 10781452
    Abstract: The present invention relates to FLT3 receptor antagonists or inhibitors of FLT3 receptor gene expression for the treatment or the prevention of pain disorders.
    Type: Grant
    Filed: September 13, 2018
    Date of Patent: September 22, 2020
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE DE MONTPELLIER
    Inventor: Jean Valmier
  • Patent number: 10765759
    Abstract: The present disclosure provides methods of treating an ocular disease or disorder. The methods involve direct administration into the eye of a conjugate comprising a biologically active polypeptide and a biocompatible polymer.
    Type: Grant
    Filed: December 8, 2016
    Date of Patent: September 8, 2020
    Assignee: The Regents of the University of California
    Inventors: Kevin E. Healy, Eda Isil Altiok, David V. Schaffer, Wesley M. Jackson
  • Patent number: 10766952
    Abstract: The present invention relates to methods for selecting a headache patient responsive to treatment with an anti-CGRP antibody and to methods for reducing headache frequency in the selected patient comprising administering an anti-CGRP antibody.
    Type: Grant
    Filed: March 1, 2018
    Date of Patent: September 8, 2020
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventor: Rami Burstein
  • Patent number: 10758560
    Abstract: Neuregulin-1 (NRG1) or a fragment thereof or vitamin B12 for use in maintaining or increasing muscle function and/or mass in an ageing subject, and/or substantially preventing or reducing muscle wasting in an ageing subject.
    Type: Grant
    Filed: December 8, 2016
    Date of Patent: September 1, 2020
    Assignee: Societe des Produits Nestle S.A.
    Inventors: Alice Pannerec, Jerome Feige
  • Patent number: 10751389
    Abstract: The present invention relates to a p75NTR neurotrophin binding protein, p75NTR(NBP), for use in the treatment of pain and/or a symptom of pain.
    Type: Grant
    Filed: August 18, 2017
    Date of Patent: August 25, 2020
    Assignee: Levicept LLD
    Inventor: Simon Westbrook
  • Patent number: 10736874
    Abstract: A method for treating pain experienced by patients with sickle cell disease.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: August 11, 2020
    Inventor: Shahin Fatholahi
  • Patent number: 10738128
    Abstract: The present disclosure relates to anti-CD39 antibodies, and antigen binding portions thereof and their use in treating cancer.
    Type: Grant
    Filed: March 13, 2019
    Date of Patent: August 11, 2020
    Assignee: Surface Oncology, Inc.
    Inventors: Scott Chappel, Andrew Lake, Michael Warren, Austin Dulak, Erik Devereaux, Pamela M. Holland, Tauqeer Zaidi, Matthew Rausch, Bianka Prinz, Nels P. Nielson, Sonia Das
  • Patent number: 10738101
    Abstract: A method for searching for a substance suppressing a target odor through cross-adaptation is provided. A method for selecting a substance inducing cross-adaptation of a target odor includes: searching olfactory receptor polypeptides to identify an olfactory receptor polypeptide responding to a causative substance of the target odor; adding a test substance, which is different from the causative substance of the target odor, to the identified olfactory receptor polypeptide to measure response thereof; and selecting the test substance which activates the response of the olfactory receptor polypeptide as the substance inducing the cross-adaptation of the target odor.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: August 11, 2020
    Assignee: Kao Corporation
    Inventors: Keiichi Yoshikawa, Naoko Saito
  • Patent number: 10729781
    Abstract: Isolated or recombinant anti-LGR4 monoclonal antibodies are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: August 4, 2020
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Qingyun Liu, Xing Gong, Kendra Carmon
  • Patent number: 10730940
    Abstract: The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: August 4, 2020
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. Gurney, Aaron Ken Sato, Christopher John Bond
  • Patent number: 10716830
    Abstract: The invention provides methods, pharmaceutical compositions and kits for treating, inhibiting and/or reducing the severity of inflammatory bowel disease and necrotizing enterocolitis in a subject in need thereof by administering an effective amount of a composition comprising an activator of ErbB4.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: July 21, 2020
    Assignee: Children's Hospital Los Angeles
    Inventor: Mark R. Frey
  • Patent number: 10702585
    Abstract: The present invention provides a pharmaceutical preparation for treating a cardiovascular disease. Particularly, the present invention provides a formula of a neuregulin pharmaceutical preparation. The formula consist of neuregulin polypeptide, a buffer, a stabilizer, an excipient, a salt, and another component, can ensure the long-term stability of the neuregulin polypeptide, and can be used for treating a heart failure patient or a patient in a risk of the heart failure.
    Type: Grant
    Filed: December 17, 2014
    Date of Patent: July 7, 2020
    Assignee: Zensun (Shanghai) Science & Technology, Co., Ltd.
    Inventor: Mingdong Zhou
  • Patent number: 10702513
    Abstract: The present invention provides methods of treating and pharmaceutical compositions useful for treating a mood disorder or depressive symptoms associated with pain, inducing analgesia and treating pain in a subject by administering a pharmaceutically effective amount of an agent capable of one or more of increasing GluA1 level, expression, concentration, or biological activity, increasing calcium permeable AMPA (? amino-3-hydroxy-5-methylisoxazole-4-propionic acid) receptor (CPAR) level, expression, concentration, or biological activity or potentiating a CPAR current. The agent may be an AMPA potentiator or ampakine. The agent may increase AMPA receptor currents by slowing the deactivation of open channels and may be, for instance, 2-pyrrolidinone, 4-[2-(phenylsulfonylamino)ethylthio]-2,6-difluorophenoxyacetamide (PEPA) or LY451646. The agent may also be a protein, RNA or DNA product.
    Type: Grant
    Filed: May 24, 2013
    Date of Patent: July 7, 2020
    Assignee: NEW YORK UNIVERSITY
    Inventors: Jing Wang, Edward Ziff
  • Patent number: 10696718
    Abstract: In some aspects, the present invention provides methods of treating a subject in need of treatment for neuropathic pain, the method comprising administering a compstatin analog to the subject. In some embodiments, the compstatin analog is administered parenterally, e.g., intravenously.
    Type: Grant
    Filed: July 9, 2018
    Date of Patent: June 30, 2020
    Assignee: Apellis Pharmaceuticals, Inc.
    Inventors: Cedric Francois, Pascal Deschatelets
  • Patent number: 10683338
    Abstract: Provided herein are specific TL1A receptor agonist proteins, nucleic acids encoding the same, and methods of treating a subject having a TL1A-associated disease or disorder. The TL1A receptor agonist proteins provided herein comprise three soluble TL1A domains and an Fc fragment. The TL1A receptor agonist proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.
    Type: Grant
    Filed: April 20, 2018
    Date of Patent: June 16, 2020
    Assignee: Apogenix AG
    Inventors: Christian Gieffers, Oliver Hill, Meinolf Thiemann, Tim Schnyder
  • Patent number: 10683332
    Abstract: Provided herein are specific LIGHT receptor agonist proteins, nucleic acids encoding the same, and methods of treating a subject having a LIGHT-associated disease or disorder. The LIGHT receptor agonist proteins provided herein comprise three soluble LIGHT domains and an Fc fragment. The LIGHT receptor agonist proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.
    Type: Grant
    Filed: April 20, 2018
    Date of Patent: June 16, 2020
    Assignee: Apogenix AG
    Inventors: Christian Gieffers, Oliver Hill, Meinolf Thiemann, Tim Schnyder